ADIAL PHARMACEUTICALS CEO Buys 232,000 Shares Ahead of Rebranding to Azora, Signals Confidence in New Colitis Drug Pipeline
Matt Davidson’s insider buy of ADIAL shares signals confidence in Azora Therapeutics’ shift to ulcerative colitis research, sparking a re‑brand‑and‑grow strategy.
4 minutes to read